TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34375387

Group type: EXPERIMENTAL
Intervention: Healthy Weight for Living (HWL)
Number of subjects: 238

Group type: COMPARATOR
Intervention: modified Diabetes Prevention Program (m-DPP)
Number of subjects: 238
Study: 34657872

Group type: EXPERIMENTAL
Intervention: Dynamic neuromuscular stabilization (DNS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Abdominal bracing (AB)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Abdominal drawing‐in maneuver (ADIM)
Number of subjects: 41
Study: 33820919

Group type: EXPERIMENTAL
Intervention: Artificial liver support system (ALSS) treatment
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Decision tree based on multivariate logistic regression model using CTP score and RPTB
Number of subjects: 375
Study: 34363198

Group type: EXPERIMENTAL
Intervention: GnRH antagonist pre-treatment for 60 days
Number of subjects: 814

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Survey response regarding COVID-19 impact
Number of subjects: 814
Study: 35066251

Group type: EXPERIMENTAL
Intervention: SYSU‐NEP virtual patients (VPs)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 34779691

Group type: EXPERIMENTAL
Intervention: Computerized executive cognitive intervention with lab‐based tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (low‐performance intervention)
Number of subjects: 0
Study: 34559902

Group type: EXPERIMENTAL
Intervention: Ixazomib (IXA), Pomalidomide (POM), Dexamethasone (DEX)
Number of subjects: 29
Study: 34927308

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Interferon beta
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Combination of glatiramer acetate and interferon beta
Number of subjects: 1008
Study: 33191846

Group type: EXPERIMENTAL
Intervention: iddEPC group (n=424) - neo-adjuvant dose-dense, dose-intensified epirubicin, paclitaxel, and cyclophosphamide
Number of subjects: 853

Group type: COMPARATOR
Intervention: paclitaxel, non-pegylated doxorubicin, and carboplatin group (n=429)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Both groups (iddEPC and paclitaxel, non-pegylated doxorubicin, and carboplatin)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: NT-proBNP measured at 6 weeks after treatment initiation
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Hemoglobin measured at 6 weeks after treatment initiation
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T
Number of subjects: 853
Study: 616117430

Group type: EXPERIMENTAL
Intervention: Copaxone (glatiramer acetate), weekly subcutaneous injections for 12 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (sham treatment)
Number of subjects: 11
Study: 36252599

Group type: EXPERIMENTAL
Intervention: Lurbinectedin plus doxorubicin (2.0 mg/m2 plus 40.0 mg/m2 on day 1 of 21-day cycles)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Control (topotecan 1.5 mg/m2 on days 1-5 of 21-day cycles; or CAV: cyclophosphamide 1000 mg/m2, doxorubicin 45.0 mg/m2, and vincristine 2.0 mg on day 1 of 21-day cycles)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Lurbinectedin plus doxorubicin
Number of subjects: 613

Group type: COMPARATOR
Intervention: Control
Number of subjects: 613
Study: 33345481

Group type: EXPERIMENTAL
Intervention: Traditional Chinese therapy of tonifying the kidney and invigorating blood circulation (TKIB), n = 22
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (oral tamoxifen tablets and vitamin E capsules), n = 20
Number of subjects: 42
Study: 35748715

Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training (RMT)
Number of subjects: 30
Study: 34160459

Group type: EXPERIMENTAL
Intervention: Food preparation program (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 22
Study: 35248121

Group type: EXPERIMENTAL
Intervention: Tourniquet application
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non-tourniquet application
Number of subjects: 130
Study: 32485112

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections (4 injections, 14 days apart)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo injections (4 injections of saline, <0.5 mL, under the skin, 14 days apart)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both PRP and placebo groups
Number of subjects: 40
Study: 35534905

Group type: EXPERIMENTAL
Intervention: Modified nominal group technique
Number of subjects: 0
Study: 33245866

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1000 mg to 2000 mg based on bodyweight and haemoglobin concentration)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Oral iron (three dried ferrous sulphate tablets of 200 mg containing 60 mg of elemental iron and 5 mg of folic acid every morning for 3 months)
Number of subjects: 230
Study: 36351736

Group type: EXPERIMENTAL
Intervention: Combined low and high frequencies NMES
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low frequency NMES
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High frequency NMES
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 56
Study: 34128358

Group type: EXPERIMENTAL
Intervention: Nasal carrageenan administered three times per day for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal carrageenan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32815394

Group type: EXPERIMENTAL
Intervention: Participation in lectures or events related to dementia
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Female students
Number of subjects: 586

Group type: COMPARATOR
Intervention: High school students
Number of subjects: 586
Study: 35588291

Group type: EXPERIMENTAL
Intervention: AR board game
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Paper board games
Number of subjects: 600

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 600
Study: 33615722

Group type: COMPARATOR
Intervention: FV diet
Number of subjects: 459

Group type: COMPARATOR
Intervention: DASH diet
Number of subjects: 459
Study: 33114125

Group type: EXPERIMENTAL
Intervention: GSM half-shell mussel
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: GSM powder
Number of subjects: 8

Group type: COMPARATOR
Intervention: GSM oil
Number of subjects: 8
Study: 36356514

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 34472754

Group type: EXPERIMENTAL
Intervention: TEAS
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sham-TEAS
Number of subjects: 94
Study: 32349134

Group type: EXPERIMENTAL
Intervention: H2S stimulation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PEA stimulation
Number of subjects: 23

Group type: COMPARATOR
Intervention: CO2 irritation
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Olfactory stimulation (H2S vs PEA)
Number of subjects: 23
Study: 35286843

Group type: EXPERIMENTAL
Intervention: CD24Fc 480 mg
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 32480076

Group type: EXPERIMENTAL
Intervention: Gait training using Hybrid Assistive Limb (HAL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 27
Study: 36608973

Group type: EXPERIMENTAL
Intervention: Enhanced mental reinstatement (EMR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control procedures
Number of subjects: 45
Study: 33407631

Group type: EXPERIMENTAL
Intervention: 400 mg of CFE
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 500 mg of CFE
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 32919517

Group type: EXPERIMENTAL
Intervention: Valaciclovir (8 g per day, twice daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Valaciclovir (for first trimester infections)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (for first trimester infections)
Number of subjects: 90
Study: 36202563

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 7038

Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 7038
Study: 32472161

Group type: EXPERIMENTAL
Intervention: Experimental group (EXP) received additional involuntary, reflexive training
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (CON) performed a standard physiotherapy program
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups (EXP and CON) during running
Number of subjects: 77
Study: 32899071

Group type: EXPERIMENTAL
Intervention: Chemotherapy containing bevacizumab (folinic acid, bolus/continuous fluorouracil, and irinotecan)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chemotherapy containing bevacizumab (modified folinic acid, bolus/continuous fluorouracil, and oxaliplatin)
Number of subjects: 55
Study: 35501762

Group type: EXPERIMENTAL
Intervention: KMC by mother and surrogate 3 times a day for up to 4 days, 60 minutes each time
Number of subjects: 70

Group type: COMPARATOR
Intervention: KMC by mother 3 times a day for up to 4 days, 60 minutes each time
Number of subjects: 70
Study: 33664161

Group type: EXPERIMENTAL
Intervention: Respiratory muscle training (RMT)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Sham training, no training, standard treatment, or breathing exercises
Number of subjects: 250
Study: 33487789

Group type: EXPERIMENTAL
Intervention: Single-session therapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multi-session therapy
Number of subjects: 40
Study: 33052760

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg every 2 weeks and apatinib 250 mg once per day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 45
Study: 34181823

Group type: EXPERIMENTAL
Intervention: Interdisciplinary evaluation (surgeon + physical therapist)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard evaluation (surgeon only)
Number of subjects: 78
Study: 32947389

Group type: EXPERIMENTAL
Intervention: Mitomycin-C (MMC) application
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no MMC treatment)
Number of subjects: 100
Study: 36001378

Group type: EXPERIMENTAL
Intervention: Cost of continued smoking frame
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Proximal risks of continued smoking frame
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Losses of not participating frame
Number of subjects: 99
Study: 35344476

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 32950645

Group type: EXPERIMENTAL
Intervention: FBT + Variety
Number of subjects: 156

Group type: COMPARATOR
Intervention: FBT
Number of subjects: 156
Study: 33491052

Group type: EXPERIMENTAL
Intervention: Induced step training (IST)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hip muscle strengthening (HST)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined training (CMB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Seated flexibility/relaxation exercises (SFR)
Number of subjects: 100
Study: 32800305

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Written Exposure Therapy (WET)
Number of subjects: 51
Study: 33417663

Group type: EXPERIMENTAL
Intervention: 1.3 g/kg/day protein plus placebo
Number of subjects: 92

Group type: COMPARATOR
Intervention: 0.8 g/kg/day protein plus placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 0.8 g/kg/day protein plus testosterone enanthate 100 mg weekly
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 1.3 g/kg/day protein plus testosterone enanthate 100 mg weekly
Number of subjects: 92
Study: 32379280

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg every 28 days) plus Tremelimumab (75 mg every 28 days for the first 4 cycles)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Durvalumab plus Tremelimumab
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Durvalumab plus Tremelimumab in microsatellite stable (MSS) patients
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Durvalumab plus Tremelimumab in MSS patients with plasma TMB of 28 variants per megabase or more
Number of subjects: 180
Study: 34278827

Group type: EXPERIMENTAL
Intervention: Neoadjuvant osimertinib with or without chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 33090219

Group type: EXPERIMENTAL
Intervention: Curative intent radical prostatectomy (RP)
Number of subjects: 19684

Group type: EXPERIMENTAL
Intervention: Radiotherapy with or without androgen deprivation therapy
Number of subjects: 19684

Group type: EXPERIMENTAL
Intervention: Score system
Number of subjects: 19684
Study: 36480703

Group type: EXPERIMENTAL
Intervention: Group member support
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group leader support
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group member and leader support
Number of subjects: 120
Study: 33916599

Group type: EXPERIMENTAL
Intervention: RT+SS
Number of subjects: 16

Group type: COMPARATOR
Intervention: RT only
Number of subjects: 16
Study: 35932065

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Tight glycemic control
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Poor glycemic control
Number of subjects: 197
Study: 34267689

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 74
Study: 32997438

Group type: EXPERIMENTAL
Intervention: Lockdown period
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Teleconsultation
Number of subjects: 124
Study: 35301577

Group type: EXPERIMENTAL
Intervention: Acupuncture plus RM
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham acupuncture plus RM
Number of subjects: 29

Group type: COMPARATOR
Intervention: RM alone
Number of subjects: 29
Study: 36178948

Group type: EXPERIMENTAL
Intervention: Higher accredited schools (platinum, gold, silver)
Number of subjects: 1454

Group type: COMPARATOR
Intervention: Lower accredited schools (bronze and below bronze)
Number of subjects: 1454
Study: 33268222

Group type: EXPERIMENTAL
Intervention: Local warming (hot pack at 40°C for 5 minutes)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 35
Study: 32990807

Group type: EXPERIMENTAL
Intervention: Deep learning system for amyloid burden estimation
Number of subjects: 121

Group type: COMPARATOR
Intervention: Visual reading without deep learning system
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Visual reading with deep learning system
Number of subjects: 121
Study: 36113984

Group type: EXPERIMENTAL
Intervention: Pre-Game Safety Huddles
Number of subjects: 343

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 343
Study: 34009486

Group type: EXPERIMENTAL
Intervention: iRARC
Number of subjects: 177
Study: 35636205

Group type: EXPERIMENTAL
Intervention: Opioid sparing (OS) protocol (patient education and perioperative multimodal analgesia)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Zero-opioid (ZO) protocol (same as OS but no opioid prescriptions at discharge)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 129
Study: 34341423

Group type: EXPERIMENTAL
Intervention: High DHM group (D group) with 359.12 mg/g DHM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low DHM group (B group) with 210.31 mg/g DHM
Number of subjects: 0
Study: 32118656

Group type: EXPERIMENTAL
Intervention: Near-Infrared Spectroscopy (NIRS)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ventilatory technique
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: NIRS and Ventilatory techniques
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 9
Study: 33231131

Group type: EXPERIMENTAL
Intervention: Perfect biomarker assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imperfect biomarker assay (sensitivity = 0.8, specificity = 0.7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarker-positive prevalence P(B = 1) = 0.2 and 0.5
Number of subjects: 0
Study: 32660725

Group type: EXPERIMENTAL
Intervention: D&C plus ACP gel
Number of subjects: 131

Group type: COMPARATOR
Intervention: D&C alone
Number of subjects: 131
Study: 35814185

Group type: EXPERIMENTAL
Intervention: 10-kHz spinal cord stimulation (SCS) + conventional medical management (CMM)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional medical management (CMM)
Number of subjects: 216
Study: 35312948

Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block (TAPB) with 30 ml 0.33% ropivacaine and dexmedetomidine 1 μg kg−1
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block (QLB) with 30 ml 0.33% ropivacaine and dexmedetomidine 1 μg kg−1
Number of subjects: 225

Group type: COMPARATOR
Intervention: General anesthesia (GA) with 30 ml 0.9% saline
Number of subjects: 225
Study: 33076762

Group type: EXPERIMENTAL
Intervention: Healthy Choices at Work programme (HCWP)
Number of subjects: 137
Study: 33349288

Group type: EXPERIMENTAL
Intervention: Family Check-Up intervention
Number of subjects: 515

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 515
Study: 32965715

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP Group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care (SC Group)
Number of subjects: 80
Study: 34465672

Group type: EXPERIMENTAL
Intervention: Treadmill training (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bicycle ergometer (group A)
Number of subjects: 30
Study: 33912695

Group type: EXPERIMENTAL
Intervention: Standard systemic therapy with local ablative radiotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard systemic therapy
Number of subjects: 100
Study: 35462028

Group type: EXPERIMENTAL
Intervention: Anodal tDCS over Broca's area
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS over Broca's area
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham/placebo control condition
Number of subjects: 15
Study: 33206263

Group type: EXPERIMENTAL
Intervention: Early antiretroviral treatment (ART) initiation irrespective of CD4 count
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control arm (ART initiation following national guidelines)
Number of subjects: 182
Study: 32378975

Group type: EXPERIMENTAL
Intervention: Bilateral neuromuscular electrical stimulation (NMES; 5 days/wk) to quadriceps muscles for 8 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 33159573

Group type: EXPERIMENTAL
Intervention: Localized heat therapy (heat pads applied for 8 hours/day, 5 days/week on one randomly selected calf)
Number of subjects: 15
Study: 33081444

Group type: EXPERIMENTAL
Intervention: Tenoten for children (1 tablet 3 times a day)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (1 tablet 3 times a day)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Tenoten for children
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 33906814

Group type: EXPERIMENTAL
Intervention: Self-compassion training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 33710154

Group type: EXPERIMENTAL
Intervention: 0.1 M STS gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 12
Study: 32007430

Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shockwave therapy (LiESWT) combined with tadalafil (5 mg/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Tadalafil (5 mg/day) alone
Number of subjects: 92
Study: 35196426

Group type: EXPERIMENTAL
Intervention: Antiseizure medications plus standard care
Number of subjects: 172

Group type: COMPARATOR
Intervention: Standard care alone (control group)
Number of subjects: 172
Study: 35278695

Group type: EXPERIMENTAL
Intervention: Rhythm control (pharmaceutical or electrical cardioversion)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Rate control (b-blocker, digoxin, calcium channel blockers)
Number of subjects: 199
Study: 33636987

Group type: EXPERIMENTAL
Intervention: Polypill for prevention of cardiovascular disease
Number of subjects: 0
Study: 32179526

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin‐piperaquine (DP) + single low dose of primaquine (SLDPQ; 0.25 mg/kg)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Dihydroartemisinin‐piperaquine (DP)
Number of subjects: 109
Study: 35915241

Group type: EXPERIMENTAL
Intervention: Restrictive fluid therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose intravenous vitamin C
Number of subjects: 0
Study: 32746734

Group type: EXPERIMENTAL
Intervention: Immersive VR experience
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Immersive VR experience after control treatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard analgesia
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall satisfaction with VR treatment
Number of subjects: 82
Study: 36002594

Group type: EXPERIMENTAL
Intervention: Modified coronally advanced tunnel (MCAT) and connective tissue graft (CTG) with enamel matrix derivative (EMD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Modified coronally advanced tunnel (MCAT) and connective tissue graft (CTG) without enamel matrix derivative (EMD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Modified coronally advanced tunnel (MCAT) and connective tissue graft (CTG) with EMD
Number of subjects: 24

Group type: COMPARATOR
Intervention: Modified coronally advanced tunnel (MCAT) and connective tissue graft (CTG) without EMD
Number of subjects: 24
Study: 33196866

Group type: EXPERIMENTAL
Intervention: Palliative radiation therapy (RT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of pain response
Number of subjects: 64
Study: 32306154

Group type: EXPERIMENTAL
Intervention: Hypertrophic (HYP) strength loading (5 sets with 10 repetitions at 80% of 1RM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Maximal (MAX) strength loading (15 sets with 1RM)
Number of subjects: 12